Multimodal treatment for inflammatory breast cancer
Identifieur interne : 00DF27 ( Main/Exploration ); précédent : 00DF26; suivant : 00DF28Multimodal treatment for inflammatory breast cancer
Auteurs : William W. Thoms Jr. [États-Unis] ; Marsha D. Mcneese [États-Unis] ; Gilbert H. Fletcher [États-Unis] ; Aman U. Buzdar [États-Unis] ; S. Eva Singletary [États-Unis] ; Mary Jane Oswald [États-Unis]Source :
- International Journal of Radiation Oncology, Biology, Physics [ 0360-3016 ] ; 1989.
Abstract
This is a retrospective study of 61 patients with clinically diagnosed breast cancer (IBC) treated with multimodality therapy between September 1977 and September 1985. All patients were scheduled to receive three courses of doxorubicin-based chemotherapy followed by mastectomy, further chemotherapy, and postoperative irradiation. Ten patients (16%) obtained a complete response, defined as either resolution of the clinical signs of inflammatory breast cancer (IBC) (4 patients) or no evidence of tumor in the mastectomy specimen (6 patients). Twenty-seven patients (45%) obtained a partial response, defined as a greater than 50% reduction in the clinical signs of inflammatory breast cancer. No response occurred in 24 patients (39%). Immediate mastectomy was done in 56 patients. Five patients whose disease was not resectable received preoperative irradiation. Nine patients at high risk for locoregional failure received postoperative irradiation immediately after mastectomy and before additional chemotherapy. Postoperative irradiation was given to the chest wall and peripheral lymphatics using standard or accelerated fractionation to a maximum dose of 60 Gy. Forty-six patients completed planned treatment including chemotherapy, surgery, and radiotherapy without failure. The minimum follow-up was 36 months. The 5-year actuarial disease-free survival was 70% for the complete response group, and 35% for the partial response group. All patients with no response failed by 34 months. The actuarial 5-year disease-free survival rate for the entire group was 27%. The 5-year actuarial locoregional control was 89% in the complete response group, 68% in the partial response group, 33% in the no response group, and 58% for all patients. Most failures were on the chest wall within the irradiated volume. Chest wall failures were more frequent in those who did not achieve brisk erythema or moist desquamation after postoperative irradiation. We conclude that multimodal treatment of patients with inflammatory breast cancer results in a low incidence of failure if complete response is obtained following initial chemotherapy. The locoregional control rate and actuarial 5-year disease-free survival for the entire group were not improved when mastectomy was done. Surgery should be done in those patients who respond adequately to chemotherapy, so that late sequelae of high-dose breast irradiation can be eliminated. Higher doses of postoperative irradiation may be required to improve local control in those patients with the poorest response to initial chemotherapy.
Url:
DOI: 10.1016/0360-3016(89)90060-6
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 004E81
- to stream Istex, to step Curation: 004E81
- to stream Istex, to step Checkpoint: 005686
- to stream Main, to step Merge: 00EB77
- to stream Main, to step Curation: 00DF27
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Multimodal treatment for inflammatory breast cancer</title>
<author><name sortKey="Thoms Jr, William W" sort="Thoms Jr, William W" uniqKey="Thoms Jr W" first="William W." last="Thoms Jr.">William W. Thoms Jr.</name>
</author>
<author><name sortKey="D Mcneese, Marsha" sort="D Mcneese, Marsha" uniqKey="D Mcneese M" first="Marsha" last="D. Mcneese">Marsha D. Mcneese</name>
</author>
<author><name sortKey="Fletcher, Gilbert H" sort="Fletcher, Gilbert H" uniqKey="Fletcher G" first="Gilbert H." last="Fletcher">Gilbert H. Fletcher</name>
</author>
<author><name sortKey="Buzdar, Aman U" sort="Buzdar, Aman U" uniqKey="Buzdar A" first="Aman U." last="Buzdar">Aman U. Buzdar</name>
</author>
<author><name sortKey="Eva Singletary, S" sort="Eva Singletary, S" uniqKey="Eva Singletary S" first="S." last="Eva Singletary">S. Eva Singletary</name>
</author>
<author><name sortKey="Jane Oswald, Mary" sort="Jane Oswald, Mary" uniqKey="Jane Oswald M" first="Mary" last="Jane Oswald">Mary Jane Oswald</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A7A82E9CB46EF0290707464BFF01EF9D6B3162F6</idno>
<date when="1989" year="1989">1989</date>
<idno type="doi">10.1016/0360-3016(89)90060-6</idno>
<idno type="url">https://api.istex.fr/document/A7A82E9CB46EF0290707464BFF01EF9D6B3162F6/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004E81</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004E81</idno>
<idno type="wicri:Area/Istex/Curation">004E81</idno>
<idno type="wicri:Area/Istex/Checkpoint">005686</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">005686</idno>
<idno type="wicri:doubleKey">0360-3016:1989:Thoms Jr W:multimodal:treatment:for</idno>
<idno type="wicri:Area/Main/Merge">00EB77</idno>
<idno type="wicri:Area/Main/Curation">00DF27</idno>
<idno type="wicri:Area/Main/Exploration">00DF27</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Multimodal treatment for inflammatory breast cancer</title>
<author><name sortKey="Thoms Jr, William W" sort="Thoms Jr, William W" uniqKey="Thoms Jr W" first="William W." last="Thoms Jr.">William W. Thoms Jr.</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The University of Texas M. D. Anderson Hospital Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="D Mcneese, Marsha" sort="D Mcneese, Marsha" uniqKey="D Mcneese M" first="Marsha" last="D. Mcneese">Marsha D. Mcneese</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The University of Texas M. D. Anderson Hospital Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fletcher, Gilbert H" sort="Fletcher, Gilbert H" uniqKey="Fletcher G" first="Gilbert H." last="Fletcher">Gilbert H. Fletcher</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The University of Texas M. D. Anderson Hospital Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Buzdar, Aman U" sort="Buzdar, Aman U" uniqKey="Buzdar A" first="Aman U." last="Buzdar">Aman U. Buzdar</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The University of Texas M. D. Anderson Hospital Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Eva Singletary, S" sort="Eva Singletary, S" uniqKey="Eva Singletary S" first="S." last="Eva Singletary">S. Eva Singletary</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The University of Texas M. D. Anderson Hospital Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jane Oswald, Mary" sort="Jane Oswald, Mary" uniqKey="Jane Oswald M" first="Mary" last="Jane Oswald">Mary Jane Oswald</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The University of Texas M. D. Anderson Hospital Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">International Journal of Radiation Oncology, Biology, Physics</title>
<title level="j" type="abbrev">ROB</title>
<idno type="ISSN">0360-3016</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1989">1989</date>
<biblScope unit="volume">17</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="739">739</biblScope>
<biblScope unit="page" to="745">745</biblScope>
</imprint>
<idno type="ISSN">0360-3016</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0360-3016</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This is a retrospective study of 61 patients with clinically diagnosed breast cancer (IBC) treated with multimodality therapy between September 1977 and September 1985. All patients were scheduled to receive three courses of doxorubicin-based chemotherapy followed by mastectomy, further chemotherapy, and postoperative irradiation. Ten patients (16%) obtained a complete response, defined as either resolution of the clinical signs of inflammatory breast cancer (IBC) (4 patients) or no evidence of tumor in the mastectomy specimen (6 patients). Twenty-seven patients (45%) obtained a partial response, defined as a greater than 50% reduction in the clinical signs of inflammatory breast cancer. No response occurred in 24 patients (39%). Immediate mastectomy was done in 56 patients. Five patients whose disease was not resectable received preoperative irradiation. Nine patients at high risk for locoregional failure received postoperative irradiation immediately after mastectomy and before additional chemotherapy. Postoperative irradiation was given to the chest wall and peripheral lymphatics using standard or accelerated fractionation to a maximum dose of 60 Gy. Forty-six patients completed planned treatment including chemotherapy, surgery, and radiotherapy without failure. The minimum follow-up was 36 months. The 5-year actuarial disease-free survival was 70% for the complete response group, and 35% for the partial response group. All patients with no response failed by 34 months. The actuarial 5-year disease-free survival rate for the entire group was 27%. The 5-year actuarial locoregional control was 89% in the complete response group, 68% in the partial response group, 33% in the no response group, and 58% for all patients. Most failures were on the chest wall within the irradiated volume. Chest wall failures were more frequent in those who did not achieve brisk erythema or moist desquamation after postoperative irradiation. We conclude that multimodal treatment of patients with inflammatory breast cancer results in a low incidence of failure if complete response is obtained following initial chemotherapy. The locoregional control rate and actuarial 5-year disease-free survival for the entire group were not improved when mastectomy was done. Surgery should be done in those patients who respond adequately to chemotherapy, so that late sequelae of high-dose breast irradiation can be eliminated. Higher doses of postoperative irradiation may be required to improve local control in those patients with the poorest response to initial chemotherapy.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Thoms Jr, William W" sort="Thoms Jr, William W" uniqKey="Thoms Jr W" first="William W." last="Thoms Jr.">William W. Thoms Jr.</name>
</region>
<name sortKey="Buzdar, Aman U" sort="Buzdar, Aman U" uniqKey="Buzdar A" first="Aman U." last="Buzdar">Aman U. Buzdar</name>
<name sortKey="D Mcneese, Marsha" sort="D Mcneese, Marsha" uniqKey="D Mcneese M" first="Marsha" last="D. Mcneese">Marsha D. Mcneese</name>
<name sortKey="Eva Singletary, S" sort="Eva Singletary, S" uniqKey="Eva Singletary S" first="S." last="Eva Singletary">S. Eva Singletary</name>
<name sortKey="Fletcher, Gilbert H" sort="Fletcher, Gilbert H" uniqKey="Fletcher G" first="Gilbert H." last="Fletcher">Gilbert H. Fletcher</name>
<name sortKey="Jane Oswald, Mary" sort="Jane Oswald, Mary" uniqKey="Jane Oswald M" first="Mary" last="Jane Oswald">Mary Jane Oswald</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00DF27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00DF27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:A7A82E9CB46EF0290707464BFF01EF9D6B3162F6 |texte= Multimodal treatment for inflammatory breast cancer }}
This area was generated with Dilib version V0.6.31. |